

CGK733

Catalog No: tcsc1322



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

905973-89-9

Formula:

$C_{23}H_{18}Cl_3FN_4O_3S$

Pathway:

Cell Cycle/DNA Damage;PI3K/Akt/mTOR

Target:

ATM/ATR;ATM/ATR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (179.91 mM)

Observed Molecular Weight:

555.84

Product Description


CGK733 is a potent **ATM/ATR** inhibitor, used for the research of cancer.

IC50 & Target: ATM/ATR^[1]

In Vitro: CGK733 (4.2 ng/μL-12.5 ng/μL) enhances taxol-induced cytotoxicity in HBV-positive HCC cells. CGK733 (4.2 ng/μL) accelerates the formation of multinucleated cells and promotes the exit of mitosis in taxol-treated HBV-positive HCC cells^[1]. CGK733

(10 μ M) causes the loss of cyclin D1 through the ubiquitin-dependent proteasomal degradation pathway in MCF-7 and T47D breast cancer cell lines. CGK733 (0.6-40 μ M) shows inhibitory activities against proliferation of LnCap prostate cancer cells, HCT116 colon cancer cells, MCF-7 and T47D estrogen receptor positive breast cancer cells, and MDA-MB436 ER negative breast cancer cells. Moreover, CGK733 inhibits proliferation of non-transformed mouse BALB/c 3T3 embryonic fibroblast cells. In addition, CGK733 (10 μ M) inhibits MCF-7 proliferation, and the effect can not be suppressed by pan-caspase inhibition^[2]. CGK733 (10 μ M) results in 1.6-fold increase in ATM reporter activity in HEK-293 cells^[3].

In Vivo: CGK733 (25 mg/kg, i.p.) increases the ATM reporter activity (reports inactivation of ATM kinase activity) compared to control mice, with 2.4-fold, 3.1-fold, and 1.3-fold changes at 1, 4, and 8 hours, respectively^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!